ADVENTRX Pharmaceuticals, Inc. announced today that Chief Technical Officer Joan M. Robbins, Ph.D., will present on the Company's EradicAide(TM) HIV therapeutic vaccine program at 5:00pm on Thursday, December 2, at a vaccines conference organized by GTCbio. The conference, entitled "Vaccines - All Things Considered", takes place at the San Francisco Airport Marriot hotel on December 2-3.
About EradicAide
EradicAide is an HIV therapeutic vaccine, composed of a cocktail of synthetic peptides which stimulate disease-fighting killer T-cells, to clear HIV-infected cells. Specific peptides in the cocktail are designed to stimulate a killer T-cell response in a manner intended to mimic how long-term nonprogressors, individuals who are HIV-infected but do not get AIDS, control HIV infection. Preclinical development for EradicAide is ongoing. The Company is the exclusive licensee of EradicAide, which was developed by researchers at M.D. Anderson Cancer Center.
About ADVENTRX
ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and viral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information can be found on the Company's website at www.adventrx.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration and other regulatory agencies. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.